NR565 ADVANCED PHARMACOLOGY MIDTERM EDAPT
2026/2027 | Rated A Review | Chamberlain | Pass Guaranteed
- A+ Graded
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (20
Questions)
Q1: A 68-year-old male with atrial fibrillation is prescribed digoxin 0.25 mg daily. He
recently started taking amiodarone for recurrent ventricular tachycardia. The NP
recognizes that the patient's risk for digoxin toxicity has increased. Which
pharmacokinetic mechanism best explains this interaction?
A. Amiodarone induces CYP3A4, increasing digoxin metabolism
B. Amiodarone reduces digoxin absorption by forming insoluble complexes in the GI
tract
C. Amiodarone inhibits P-glycoprotein, decreasing renal clearance of digoxin [CORRECT]
D. Amiodarone displaces digoxin from albumin binding sites, increasing free drug
concentration
Correct Answer: C
Rationale: Amiodarone is a potent inhibitor of P-glycoprotein (P-gp), the efflux
transporter responsible for digoxin secretion into the renal tubule and biliary tract.
Inhibition of P-gp reduces digoxin clearance by approximately 50%, effectively doubling
serum digoxin levels and precipitating toxicity even at standard doses. Digoxin is not
significantly metabolized by CYP450 enzymes, making option A incorrect. Option B
describes an interaction seen with antacids or cholestyramine, not amiodarone. Option
D is incorrect because digoxin has minimal protein binding (approximately 25%), so
displacement interactions are clinically insignificant. EDAPT REVIEW: P-gp inhibition is a
critical mechanism for digoxin drug interactions—always reduce digoxin dose by 50%
when initiating amiodarone. RATED A ✓
,Q2: A nurse practitioner is counseling a patient starting phenytoin for seizure
prophylaxis. The NP explains that at therapeutic doses, phenytoin follows zero-order
elimination kinetics. Which statement best describes the clinical implication of this
pharmacokinetic property?
A. A constant percentage of the drug is eliminated per unit time regardless of plasma
concentration
B. A constant amount of the drug is eliminated per unit time, and small dose increases
can cause disproportionate plasma level increases [CORRECT]
C. The drug accumulates linearly with each dose until steady state is achieved in 3-5
half-lives
D. The elimination rate is directly proportional to the plasma concentration at all dose
ranges
Correct Answer: B
Rationale: Phenytoin exhibits capacity-limited (zero-order) elimination at therapeutic
concentrations because CYP2C9 and CYP2C19 become saturated. In zero-order
kinetics, a fixed amount of drug is eliminated per unit time rather than a fixed
percentage. This means that once enzyme saturation occurs, even small dose
increments can produce disproportionately large increases in plasma concentration,
dramatically increasing toxicity risk. Option A describes first-order kinetics. Option C
describes linear accumulation but fails to capture the non-linear nature of phenytoin
elimination. Option D describes first-order kinetics where elimination rate is proportional
to concentration. EDAPT REVIEW: Phenytoin requires careful therapeutic drug
monitoring because its pharmacokinetics transition from first-order to zero-order within
the therapeutic range. RATED A ✓
Q3: A 45-year-old patient with major depressive disorder is prescribed fluoxetine 20 mg
daily. The NP explains that steady-state concentration will be reached after
approximately 5 half-lives. Given fluoxetine's half-life of 1-3 days (and its active
metabolite norfluoxetine's half-life of 4-16 days), approximately how long will it take to
achieve steady-state plasma concentrations?
A. 3-5 days
B. 7-10 days
C. 2-4 weeks [CORRECT]
D. 6-8 hours
,Correct Answer: C
Rationale: Steady-state concentration is achieved after approximately 5 half-lives of the
active compound. Fluoxetine's active metabolite norfluoxetine has an extremely long
half-life of 4-16 days. Using the longest half-life for conservative estimation (16 days × 5
= 80 days) or even the average (10 days × 5 = 50 days), clinical steady-state is generally
considered to occur within 2-4 weeks for practical purposes. Option A and B
significantly underestimate the time required due to norfluoxetine's prolonged
elimination. Option D is absurdly short and reflects confusion with immediate-release
formulations of other drug classes. EDAPT REVIEW: Fluoxetine's long half-life is
advantageous for medication adherence but requires a 5-week washout before starting
MAOIs to prevent serotonin syndrome. RATED A ✓
Q4: A patient with chronic kidney disease (CKD Stage 4, eGFR 22 mL/min) requires
dosing adjustment for gentamicin. The NP calculates the appropriate dose using the
Cockcroft-Gault formula. Which patient parameter is most critical for accurate
estimation of renal drug clearance in this equation?
A. Ideal body weight or adjusted body weight for obese patients [CORRECT]
B. Total body weight regardless of body composition
C. Lean body mass estimated by bioelectrical impedance
D. Body surface area calculated using the Mosteller formula
Correct Answer: A
Rationale: The Cockcroft-Gault equation estimates creatinine clearance using age,
serum creatinine, and weight. For obese patients (BMI >30 kg/m²), total body weight
overestimates muscle mass and creatinine production, while ideal body weight may
underestimate it. Adjusted body weight (ideal body weight + 0.4 × [actual weight − ideal
weight]) provides the most accurate estimation for aminoglycoside dosing in obesity.
Option B leads to dose underestimation in obesity. Option C, while potentially accurate,
is not the standard parameter used in the Cockcroft-Gault equation. Option D describes
the BSA method used for chemotherapy dosing, not the Cockcroft-Gault equation.
EDAPT REVIEW: Always use adjusted body weight for obese patients when calculating
, aminoglycoside doses via Cockcroft-Gault to prevent nephrotoxicity from overdosing.
RATED A ✓
Q5: A 55-year-old patient with hypertension is prescribed propranolol. The NP
understands that propranolol undergoes extensive first-pass metabolism. Which
statement accurately describes the clinical significance of high first-pass metabolism?
A. Oral bioavailability is significantly reduced, requiring higher oral doses than IV doses
to achieve equivalent plasma concentrations [CORRECT]
B. The drug is primarily eliminated unchanged by the kidneys, necessitating renal dose
adjustment
C. First-pass metabolism increases the rate of drug absorption from the GI tract
D. The drug bypasses hepatic metabolism entirely when administered orally
Correct Answer: A
Rationale: First-pass metabolism refers to the extensive hepatic extraction of a drug
after oral administration before it reaches systemic circulation. Propranolol has an oral
bioavailability of only 25-30% due to high hepatic first-pass metabolism, meaning oral
doses must be substantially higher than IV doses to achieve equivalent therapeutic
effects. Option B is incorrect because propranolol is hepatically metabolized, not renally
eliminated. Option C reverses the concept—first-pass metabolism reduces, not
increases, systemic availability. Option D is incorrect because oral administration
specifically exposes the drug to first-pass hepatic metabolism, whereas IV
administration bypasses it. EDAPT REVIEW: Drugs with high first-pass metabolism
(propranolol, nitroglycerin, morphine) show marked differences between oral and
parenteral dosing. RATED A ✓
Q6: A patient taking warfarin (INR 2.5, therapeutic range) is started on a 7-day course of
trimethoprim-sulfamethoxazole for a urinary tract infection. The NP anticipates which
pharmacokinetic interaction mechanism?
A. Sulfamethoxazole induces CYP2C9, accelerating warfarin metabolism and
decreasing INR
B. Sulfamethoxazole inhibits CYP2C9 and displaces warfarin from protein binding sites,
increasing free warfarin and INR [CORRECT]
C. Trimethoprim enhances vitamin K synthesis in the gut, antagonizing warfarin effects
D. The combination increases warfarin renal excretion, requiring dose escalation
2026/2027 | Rated A Review | Chamberlain | Pass Guaranteed
- A+ Graded
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (20
Questions)
Q1: A 68-year-old male with atrial fibrillation is prescribed digoxin 0.25 mg daily. He
recently started taking amiodarone for recurrent ventricular tachycardia. The NP
recognizes that the patient's risk for digoxin toxicity has increased. Which
pharmacokinetic mechanism best explains this interaction?
A. Amiodarone induces CYP3A4, increasing digoxin metabolism
B. Amiodarone reduces digoxin absorption by forming insoluble complexes in the GI
tract
C. Amiodarone inhibits P-glycoprotein, decreasing renal clearance of digoxin [CORRECT]
D. Amiodarone displaces digoxin from albumin binding sites, increasing free drug
concentration
Correct Answer: C
Rationale: Amiodarone is a potent inhibitor of P-glycoprotein (P-gp), the efflux
transporter responsible for digoxin secretion into the renal tubule and biliary tract.
Inhibition of P-gp reduces digoxin clearance by approximately 50%, effectively doubling
serum digoxin levels and precipitating toxicity even at standard doses. Digoxin is not
significantly metabolized by CYP450 enzymes, making option A incorrect. Option B
describes an interaction seen with antacids or cholestyramine, not amiodarone. Option
D is incorrect because digoxin has minimal protein binding (approximately 25%), so
displacement interactions are clinically insignificant. EDAPT REVIEW: P-gp inhibition is a
critical mechanism for digoxin drug interactions—always reduce digoxin dose by 50%
when initiating amiodarone. RATED A ✓
,Q2: A nurse practitioner is counseling a patient starting phenytoin for seizure
prophylaxis. The NP explains that at therapeutic doses, phenytoin follows zero-order
elimination kinetics. Which statement best describes the clinical implication of this
pharmacokinetic property?
A. A constant percentage of the drug is eliminated per unit time regardless of plasma
concentration
B. A constant amount of the drug is eliminated per unit time, and small dose increases
can cause disproportionate plasma level increases [CORRECT]
C. The drug accumulates linearly with each dose until steady state is achieved in 3-5
half-lives
D. The elimination rate is directly proportional to the plasma concentration at all dose
ranges
Correct Answer: B
Rationale: Phenytoin exhibits capacity-limited (zero-order) elimination at therapeutic
concentrations because CYP2C9 and CYP2C19 become saturated. In zero-order
kinetics, a fixed amount of drug is eliminated per unit time rather than a fixed
percentage. This means that once enzyme saturation occurs, even small dose
increments can produce disproportionately large increases in plasma concentration,
dramatically increasing toxicity risk. Option A describes first-order kinetics. Option C
describes linear accumulation but fails to capture the non-linear nature of phenytoin
elimination. Option D describes first-order kinetics where elimination rate is proportional
to concentration. EDAPT REVIEW: Phenytoin requires careful therapeutic drug
monitoring because its pharmacokinetics transition from first-order to zero-order within
the therapeutic range. RATED A ✓
Q3: A 45-year-old patient with major depressive disorder is prescribed fluoxetine 20 mg
daily. The NP explains that steady-state concentration will be reached after
approximately 5 half-lives. Given fluoxetine's half-life of 1-3 days (and its active
metabolite norfluoxetine's half-life of 4-16 days), approximately how long will it take to
achieve steady-state plasma concentrations?
A. 3-5 days
B. 7-10 days
C. 2-4 weeks [CORRECT]
D. 6-8 hours
,Correct Answer: C
Rationale: Steady-state concentration is achieved after approximately 5 half-lives of the
active compound. Fluoxetine's active metabolite norfluoxetine has an extremely long
half-life of 4-16 days. Using the longest half-life for conservative estimation (16 days × 5
= 80 days) or even the average (10 days × 5 = 50 days), clinical steady-state is generally
considered to occur within 2-4 weeks for practical purposes. Option A and B
significantly underestimate the time required due to norfluoxetine's prolonged
elimination. Option D is absurdly short and reflects confusion with immediate-release
formulations of other drug classes. EDAPT REVIEW: Fluoxetine's long half-life is
advantageous for medication adherence but requires a 5-week washout before starting
MAOIs to prevent serotonin syndrome. RATED A ✓
Q4: A patient with chronic kidney disease (CKD Stage 4, eGFR 22 mL/min) requires
dosing adjustment for gentamicin. The NP calculates the appropriate dose using the
Cockcroft-Gault formula. Which patient parameter is most critical for accurate
estimation of renal drug clearance in this equation?
A. Ideal body weight or adjusted body weight for obese patients [CORRECT]
B. Total body weight regardless of body composition
C. Lean body mass estimated by bioelectrical impedance
D. Body surface area calculated using the Mosteller formula
Correct Answer: A
Rationale: The Cockcroft-Gault equation estimates creatinine clearance using age,
serum creatinine, and weight. For obese patients (BMI >30 kg/m²), total body weight
overestimates muscle mass and creatinine production, while ideal body weight may
underestimate it. Adjusted body weight (ideal body weight + 0.4 × [actual weight − ideal
weight]) provides the most accurate estimation for aminoglycoside dosing in obesity.
Option B leads to dose underestimation in obesity. Option C, while potentially accurate,
is not the standard parameter used in the Cockcroft-Gault equation. Option D describes
the BSA method used for chemotherapy dosing, not the Cockcroft-Gault equation.
EDAPT REVIEW: Always use adjusted body weight for obese patients when calculating
, aminoglycoside doses via Cockcroft-Gault to prevent nephrotoxicity from overdosing.
RATED A ✓
Q5: A 55-year-old patient with hypertension is prescribed propranolol. The NP
understands that propranolol undergoes extensive first-pass metabolism. Which
statement accurately describes the clinical significance of high first-pass metabolism?
A. Oral bioavailability is significantly reduced, requiring higher oral doses than IV doses
to achieve equivalent plasma concentrations [CORRECT]
B. The drug is primarily eliminated unchanged by the kidneys, necessitating renal dose
adjustment
C. First-pass metabolism increases the rate of drug absorption from the GI tract
D. The drug bypasses hepatic metabolism entirely when administered orally
Correct Answer: A
Rationale: First-pass metabolism refers to the extensive hepatic extraction of a drug
after oral administration before it reaches systemic circulation. Propranolol has an oral
bioavailability of only 25-30% due to high hepatic first-pass metabolism, meaning oral
doses must be substantially higher than IV doses to achieve equivalent therapeutic
effects. Option B is incorrect because propranolol is hepatically metabolized, not renally
eliminated. Option C reverses the concept—first-pass metabolism reduces, not
increases, systemic availability. Option D is incorrect because oral administration
specifically exposes the drug to first-pass hepatic metabolism, whereas IV
administration bypasses it. EDAPT REVIEW: Drugs with high first-pass metabolism
(propranolol, nitroglycerin, morphine) show marked differences between oral and
parenteral dosing. RATED A ✓
Q6: A patient taking warfarin (INR 2.5, therapeutic range) is started on a 7-day course of
trimethoprim-sulfamethoxazole for a urinary tract infection. The NP anticipates which
pharmacokinetic interaction mechanism?
A. Sulfamethoxazole induces CYP2C9, accelerating warfarin metabolism and
decreasing INR
B. Sulfamethoxazole inhibits CYP2C9 and displaces warfarin from protein binding sites,
increasing free warfarin and INR [CORRECT]
C. Trimethoprim enhances vitamin K synthesis in the gut, antagonizing warfarin effects
D. The combination increases warfarin renal excretion, requiring dose escalation
